Quoin Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 results slightly missed consensus on the bottom line, with a Net Loss of $5.37M vs. the $5.29M expected, primarily driven by a 76.9% YoY surge in R&D investment. GAAP EPS of -$1.90 was lower than the mean estimate of -$1.61, impacted by accelerated clinical trials for QRX003 and QRX009. While pre-revenue as expected, the company received FDA IND clearance for Peeling Skin Syndrome and maintains a cash runway into 2027.